The Marty Makary sack trade
The FDA’s rare disease area is coming under increasing public and political scrutiny. There have now been 8 Wallstreet Journal articles as well as another article in Bloomberg calling for Marty Makary’s resignation. Under his tenure, several promising drug candidates …